What does QUERTON ENDOCRINOLOGIE do?

QUERTON ENDOCRINOLOGIE is a specialist medical practice in Profondeville. Private Limited, started on 15 May 2014, 1 establishment.

What is the address of QUERTON ENDOCRINOLOGIE?

The registered office of QUERTON ENDOCRINOLOGIE is located at Rue Léon François(B.V.) 50 box B, 5170 Profondeville.

Is QUERTON ENDOCRINOLOGIE still active?

Yes. According to the CBE (31 October 2026) QUERTON ENDOCRINOLOGIE is active, legal situation “Normale toestand”, started on 15 May 2014.

Is QUERTON ENDOCRINOLOGIE registered on Peppol?

Yes, QUERTON ENDOCRINOLOGIE is registered on the Peppol network with ID 0208:0552710057.

What is the enterprise number of QUERTON ENDOCRINOLOGIE?

The enterprise number of QUERTON ENDOCRINOLOGIE is BE0552710057.

When was QUERTON ENDOCRINOLOGIE founded?

QUERTON ENDOCRINOLOGIE was founded on 15 May 2014.

Who are the directors of QUERTON ENDOCRINOLOGIE?

According to the 2025 annual accounts, the directors of QUERTON ENDOCRINOLOGIE are: Laurent QUERTON.

Is QUERTON ENDOCRINOLOGIE a reliable company?

Databakkes does not pass judgement; this is what the sources say: Active according to the CBE since 15 May 2014; 5 annual accounts filed, latest fiscal year 2025; 1 directors known from the annual account.

How much profit did QUERTON ENDOCRINOLOGIE make in 2025?

QUERTON ENDOCRINOLOGIE posted a profit after taxes of € 109,638 in financial year 2025.

What is the revenue of QUERTON ENDOCRINOLOGIE?

As a small company, QUERTON ENDOCRINOLOGIE is not required to publish revenue in its annual accounts. In financial year 2025, its added value was € 198,585.

QUERTON ENDOCRINOLOGIE (Private Limited) - Profondeville

Dossier QUERTON ENDOCRINOLOGIE, printed on 31 October 2026 from databakkes.be/en/0552710057/querton-endocrinologie. Sources: CBE, National Bank of Belgium, Belgian Official Gazette.

Financials

Financial year 2025

QUERTON ENDOCRINOLOGIE from Profondeville, company number BE0552710057, closed financial year 2025 with a result of € 109,638 after tax. For that financial year QUERTON ENDOCRINOLOGIE recorded a gross margin of € 198,585 and equity of € 18,674. Compared with financial year 2024, the result moved from € 131,998 to € 109,638. The company is profitable. The buffer is growing. High debts against a small own buffer. The most recent annual accounts were filed with the National Bank of Belgium on March 27, 2026.

What it is worth Growing

€ 18,674

Assets minus debts, by the books. What is left if everything were sold and paid today.

Profit Healthy

€ 109,638

▼ 17% vs 2024

Profit after tax over the fiscal year.

Cash in the bank

€ 51,108

▼ 36% vs 2024

Cash and bank balances on the last day of the fiscal year.

Where the profit goes Pays out

€ 109,600 paid out

100 % of the profit went to the shareholders, the rest stayed in the company.

People and assets in 2025

Full-time equivalents estimate The annual accounts report no full-time equivalents. A micro company with one active director is usually run by that person; this is an assumption, not a figure from the source.

≈ 1

No payroll staff. One director, so that person most likely runs the business.

Vehicles and equipment

€ 11,881

▼ 30% vs 2024

Book value of vehicles, furniture and equipment.

Debts at end 2025

Bank debt

None

No bank loans on the last day of the fiscal year.

Key figures per fiscal year Download key figures (CSV)
	2022	2023	2024	2025	Change 2024 → 2025
Gross margin	€ 130,236 Gross margin 2022: € 130,236 First fiscal year in the series	€ 177,022 Gross margin 2023: € 177,022 ▲ 36% vs 2022 (€ 130,236) Favourable step	€ 178,086 Gross margin 2024: € 178,086 ▲ 1% vs 2023 (€ 177,022) Favourable step	€ 198,585 Gross margin 2025: € 198,585 ▲ 12% vs 2024 (€ 178,086) Favourable step	▲ 12%
Profit after taxes	€ 90,193 Profit after taxes 2022: € 90,193 First fiscal year in the series	€ 121,358 Profit after taxes 2023: € 121,358 ▲ 35% vs 2022 (€ 90,193) Favourable step	€ 131,998 Profit after taxes 2024: € 131,998 ▲ 9% vs 2023 (€ 121,358) Favourable step	€ 109,638 Profit after taxes 2025: € 109,638 ▼ 17% vs 2024 (€ 131,998) Unfavourable step	▼ 17%
Equity	€ 18,681 Equity 2022: € 18,681 First fiscal year in the series	€ 18,639 Equity 2023: € 18,639 Unchanged (€ 18,681) Unfavourable step	€ 18,637 Equity 2024: € 18,637 Unchanged (€ 18,639) Unfavourable step	€ 18,674 Equity 2025: € 18,674 Unchanged (€ 18,637) Favourable step
Total debts	€ 96,854 Total debts 2022: € 96,854 First fiscal year in the series	€ 124,783 Total debts 2023: € 124,783 ▲ 29% vs 2022 (€ 96,854) Unfavourable step	€ 132,000 Total debts 2024: € 132,000 ▲ 6% vs 2023 (€ 124,783) Unfavourable step	€ 109,600 Total debts 2025: € 109,600 ▼ 17% vs 2024 (€ 132,000) Favourable step	▼ 17%
Cash	€ 37,637 Cash 2022: € 37,637 First fiscal year in the series	€ 55,492 Cash 2023: € 55,492 ▲ 47% vs 2022 (€ 37,637) Favourable step	€ 80,025 Cash 2024: € 80,025 ▲ 44% vs 2023 (€ 55,492) Favourable step	€ 51,108 Cash 2025: € 51,108 ▼ 36% vs 2024 (€ 80,025) Unfavourable step	▼ 36%
Retained profit	€ 81 Retained profit 2022: € 81 First fiscal year in the series	€ 39 Retained profit 2023: € 39 ▼ 52% vs 2022 (€ 81) Unfavourable step	€ 37 Retained profit 2024: € 37 ▼ 6% vs 2023 (€ 39) Unfavourable step	€ 74 Retained profit 2025: € 74 ▲ 103% vs 2024 (€ 37) Favourable step	▲ 103%
Dividend	€ 92,000 Dividend 2022: € 92,000 First fiscal year in the series	€ 121,400 Dividend 2023: € 121,400 ▲ 32% vs 2022 (€ 92,000) Unchanged	€ 132,000 Dividend 2024: € 132,000 ▲ 9% vs 2023 (€ 121,400) Unchanged	€ 109,600 Dividend 2025: € 109,600 ▼ 17% vs 2024 (€ 132,000) Unchanged	▼ 17%
Balance sheet total	€ 115,535 Balance sheet total 2022: € 115,535 First fiscal year in the series	€ 143,422 Balance sheet total 2023: € 143,422 ▲ 24% vs 2022 (€ 115,535) Unchanged	€ 150,637 Balance sheet total 2024: € 150,637 ▲ 5% vs 2023 (€ 143,422) Unchanged	€ 128,274 Balance sheet total 2025: € 128,274 ▼ 15% vs 2024 (€ 150,637) Unchanged	▼ 15%

Key figures of QUERTON ENDOCRINOLOGIE, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.

What happened to QUERTON ENDOCRINOLOGIE?

What happened at QUERTON ENDOCRINOLOGIE in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:

Mar 27, 2026 New annual accounts for financial year 2025: profit of € 109,638 (▼ 17% vs 2024). Source: NBB ↗
May 15, 2014 New establishment in Profondeville. KBO
2014 Laurent QUERTON became a director. NBB
May 15, 2014 Start of the company according to the CBE. KBO

In short

From € 90,193 profit in 2022 to € 109,638 profit in 2025.

Paid € 129,866 in corporate taxes since 2022.

Best year ever: 2024, with € 131,998 profit.

Paid out € 455,000 in dividends to the owners in total.

Original PDFs at the National Bank ↗

Management

Laurent QUERTON

QUERTON ENDOCRINOLOGIE

Behind QUERTON ENDOCRINOLOGIE is Laurent QUERTON.

Directors

According to the 2025 annual accounts

Laurent QUERTON

Director

since 2014

Establishments

Establishment units

Physical locations of this company

Registered office

Rue Léon François(B.V.) 50 box B

5170 Profondeville

Who else lives here?

A building full of entrepreneurs or one very busy letterbox? Another 1 companies are registered at this address.

All companies at this address →

Association des Copropriétaires Résidence Les Terrasses du Bois des Chênes I à Bois-de-Villers, rue Léon François, 50.

What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.

Details

Company number: 0552.710.057
VAT number: BE 0552.710.057
Registered office: Rue Léon François(B.V.) 50 bus B, 5170 Profondeville
Names & denominations: QUERTON ENDOCRINOLOGIE
Enterprise type: Rechtspersoon
Legal form: Private limited company
Legal situation: Normale toestand
Start date: 15 May 2014
Peppol: Active · Active since 19 Feb 2025
Contact: [email protected] 0495/45.49.83
Activities · NACE: Activiteiten van medisch specialisten

View on CBE Public ↗ Annual accounts (NBB) ↗